• Consensus Rating: Moderate Buy
  • Consensus Price Target: $51.33
  • Forecasted Upside: 29.14%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$39.75
+0 (0.00%)
Get New NuVasive Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NUVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NUVA

Analyst Price Target is $51.33
▲ +29.14% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for NuVasive in the last 3 months. The average price target is $51.33, with a high forecast of $58.00 and a low forecast of $45.00. The average price target represents a 29.14% upside from the last price of $39.75.

This chart shows the closing price for NUVA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 investment analysts is to moderate buy stock in NuVasive. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/20/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/18/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/16/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/15/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/14/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/13/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/12/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/4/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$40.00 ➝ $45.00Low
8/4/2023BarclaysBoost TargetOverweight ➝ Overweight$56.00 ➝ $58.00Low
7/19/2023Truist FinancialBoost Target$48.00 ➝ $51.00Low
5/12/2023BarclaysBoost Target$53.00 ➝ $56.00Low
2/23/2023JPMorgan Chase & Co.Boost TargetNeutral$38.00 ➝ $45.00Low
2/23/2023Morgan StanleyBoost TargetEqual Weight$44.00 ➝ $44.50Low
2/10/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$47.00 ➝ $57.72Low
2/10/2023Truist FinancialDowngradeBuy ➝ Hold$51.00 ➝ $52.50Low
2/10/2023CitigroupDowngradeBuy ➝ Neutral$63.00 ➝ $52.00Low
2/9/2023Piper SandlerDowngradeOverweight ➝ NeutralLow
1/31/2023Truist FinancialBoost TargetBuy$48.00 ➝ $51.00Low
1/6/2023Needham & Company LLCDowngradeBuy ➝ HoldLow
11/15/2022Robert W. BairdLower Target$46.00N/A
11/10/2022CowenLower Target$65.00 ➝ $50.00Low
11/10/2022Royal Bank of CanadaLower TargetOutperform$63.00 ➝ $58.00Low
11/10/2022Morgan StanleyLower TargetEqual Weight$48.00 ➝ $44.00Low
11/10/2022Needham & Company LLCLower TargetBuy$53.00 ➝ $52.00Low
11/10/2022CowenLower Target$65.00 ➝ $50.00Low
11/10/2022Wells Fargo & CompanyLower TargetOverweight$62.00 ➝ $47.00Low
11/10/2022Piper SandlerLower TargetOverweight$60.00 ➝ $50.00Low
10/17/2022BarclaysInitiated CoverageOverweight$53.00Low
10/13/2022Robert W. BairdLower Target$54.00Low
10/12/2022Jefferies Financial GroupInitiated CoverageHold$45.00Low
10/7/2022Morgan StanleyLower TargetEqual Weight$54.00 ➝ $48.00Low
10/7/2022Truist FinancialLower TargetBuy$63.00 ➝ $58.00Low
10/7/2022Robert W. BairdLower TargetNeutral$60.00 ➝ $54.00Low
10/5/2022CitigroupLower Target$65.00 ➝ $63.00Low
9/30/2022Needham & Company LLCLower TargetBuy$67.00 ➝ $53.00Low
8/5/2022Canaccord Genuity GroupBoost Target$50.00 ➝ $55.00Low
8/4/2022Piper SandlerLower TargetOverweight$80.00 ➝ $60.00N/A
7/22/2022Truist FinancialLower Target$63.00Low
7/15/2022Morgan StanleyLower TargetEqual Weight$62.00 ➝ $54.00Low
4/13/2022Truist FinancialInitiated CoverageBuy$60.00 ➝ $65.00N/A
3/28/2022Wells Fargo & CompanyInitiated CoverageOverweight$58.00High
3/24/2022Needham & Company LLCReiterated RatingBuy$64.00Low
2/24/2022Needham & Company LLCReiterated RatingBuy$64.00High
1/7/2022Morgan StanleyLower TargetEqual Weight$62.00 ➝ $60.00Medium
12/21/2021Truist FinancialLower TargetBuy$75.00 ➝ $60.00High
12/9/2021Royal Bank of CanadaInitiated CoverageOutperform$60.00Medium
11/10/2021Truist FinancialLower TargetBuy$80.00 ➝ $75.00High
11/10/2021Credit Suisse GroupLower TargetOutperform$84.00 ➝ $83.00High
11/10/2021UBS GroupLower TargetSell$59.00 ➝ $54.00High
11/10/2021CitigroupLower TargetBuy$82.00 ➝ $70.00High
11/10/2021Needham & Company LLCLower TargetPositive ➝ Buy$73.00 ➝ $64.00High
10/28/2021Loop CapitalInitiated CoverageHoldMedium
10/27/2021Needham & Company LLCLower TargetBuy$80.00 ➝ $73.00Low
10/27/2021JMP SecuritiesReiterated RatingHoldMedium
10/14/2021JPMorgan Chase & Co.Lower TargetNeutral$70.00 ➝ $60.00High
7/29/2021Needham & Company LLCReiterated RatingBuyHigh
5/7/2021Morgan StanleyBoost TargetEqual Weight$70.00 ➝ $74.00Low
5/6/2021Needham & Company LLCBoost TargetBuy$70.00 ➝ $80.00High
5/6/2021Piper SandlerBoost TargetOverweight$75.00 ➝ $80.00High
4/27/2021Truist FinancialBoost Target$68.00 ➝ $80.00High
4/19/2021Morgan StanleyBoost TargetEqual Weight$65.00 ➝ $70.00Low
3/26/2021Piper SandlerBoost TargetOverweight$68.00 ➝ $75.00Low
3/25/2021CitigroupBoost Target$68.00 ➝ $80.00Medium
3/1/2021Piper SandlerBoost Target$63.00 ➝ $68.00Low
3/1/2021Morgan StanleyBoost TargetEqual Weight$53.00 ➝ $65.00Low
1/29/2021Piper SandlerLower TargetOverweight$75.00 ➝ $63.00High
1/6/2021Needham & Company LLCReiterated RatingBuy$74.00N/A
12/16/2020Smith Barney CitigroupUpgradeNeutral ➝ Buy$60.00High
12/15/2020Morgan StanleyBoost TargetEqual Weight$52.00 ➝ $53.00Medium
12/15/2020Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$48.00Medium
11/2/2020Morgan StanleyLower TargetEqual Weight$63.00 ➝ $52.00Medium
10/30/2020BTIG ResearchDowngradeBuy ➝ NeutralHigh
10/30/2020SVB LeerinkLower TargetOutperform$70.00 ➝ $65.00High
10/30/2020Robert W. BairdDowngradeOutperform ➝ Neutral$76.00 ➝ $56.00High
10/19/2020Stifel NicolausInitiated CoverageBuy$64.00Low
8/5/2020Northland SecuritiesReiterated RatingHoldHigh
7/21/2020Morgan StanleyReiterated RatingHoldLow
7/21/2020Credit Suisse GroupReiterated RatingBuy$74.00Low
7/20/2020Needham & Company LLCReiterated RatingBuy$74.00High
6/25/2020Northland SecuritiesInitiated CoverageMarket Perform$65.00High
6/23/2020Needham & Company LLCUpgradeHold ➝ Buy$74.00Medium
6/12/2020Credit Suisse GroupReiterated RatingBuy$74.00Low
6/5/2020Wells Fargo & CompanyBoost TargetEqual Weight$62.00 ➝ $63.00High
5/29/2020Credit Suisse GroupReiterated RatingBuy$74.00Medium
5/7/2020Credit Suisse GroupReiterated RatingBuy$74.00High
5/7/2020UBS GroupLower TargetSell$65.00 ➝ $55.00Medium
5/7/2020CitigroupBoost TargetNeutral$55.00 ➝ $58.00Medium
5/7/2020Piper SandlerLower TargetOverweight$90.00 ➝ $75.00Medium
5/4/2020JPMorgan Chase & Co.Lower TargetNeutral$80.00 ➝ $60.00Medium
4/19/2020Robert W. BairdUpgradeNeutral ➝ OutperformMedium
4/14/2020Piper SandlerReiterated RatingBuy$90.00High
4/14/2020Needham & Company LLCReiterated RatingHoldHigh
4/8/2020Wells Fargo & CompanyLower TargetEqual Weight$79.00 ➝ $56.00High
4/8/2020Robert W. BairdUpgradeNeutral ➝ Outperform$82.00 ➝ $66.00High
3/27/2020Morgan StanleyLower TargetEqual Weight$82.00 ➝ $63.00Medium
3/27/2020CitigroupLower TargetNeutral$68.00 ➝ $55.00High
3/6/2020Credit Suisse GroupLower TargetOutperform$92.00 ➝ $86.00High
3/4/2020CitigroupInitiated CoverageNeutral$68.00Medium
2/21/2020Cantor FitzgeraldBoost TargetIn-Line ➝ Neutral$68.00 ➝ $85.00High
2/21/2020Credit Suisse GroupBoost TargetIn-Line ➝ Outperform$87.00 ➝ $92.00High
1/14/2020Robert W. BairdBoost TargetNeutral$74.00 ➝ $82.00Low
1/8/2020Credit Suisse GroupBoost TargetOutperform$76.00 ➝ $87.00Low
1/7/2020SunTrust BanksInitiated CoverageBuy$93.00Low
1/2/2020Piper Sandler CompaniesReiterated RatingBuy$80.00Low
12/17/2019Morgan StanleyBoost TargetEqual Weight$73.00 ➝ $82.00Low
12/13/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$72.00 ➝ $92.00High
12/12/2019Wells Fargo & CompanyBoost TargetEqual Weight$70.00 ➝ $74.00Low
9/24/2019Royal Bank of CanadaBoost TargetOutperform$74.00Low
9/9/2019UBS GroupBoost TargetSell$51.00 ➝ $55.00Low
8/9/2019CowenSet TargetBuy$75.00Low
8/9/2019BTIG ResearchSet TargetBuy$71.00N/A
8/9/2019BMO Capital MarketsBoost TargetMarket Perform$54.00 ➝ $68.00Low
8/8/2019Needham & Company LLCReiterated RatingHoldLow
8/7/2019Royal Bank of CanadaSet TargetBuy$70.00Low
7/31/2019Piper Sandler CompaniesSet TargetBuy$72.00Low
7/31/2019Royal Bank of CanadaSet TargetBuy$70.00Low
7/31/2019Morgan StanleyBoost TargetEqual Weight$57.00 ➝ $67.00High
7/29/2019Robert W. BairdDowngradeOutperform ➝ Neutral$66.00Low
7/1/2019BTIG ResearchReiterated RatingBuy$65.00Medium
(Data available from 6/13/2019 forward)

News Sentiment Rating

-0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/16/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/15/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/14/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/13/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
NuVasive logo
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.
Read More

Today's Range

Now: $39.75
Low: $39.75
High: $39.75

50 Day Range

MA: $39.64
Low: $38.12
High: $40.66

52 Week Range

Now: $39.75
Low: $35.17
High: $49.53

Volume

N/A

Average Volume

1,159,125 shs

Market Capitalization

$2.08 billion

P/E Ratio

79.50

Dividend Yield

N/A

Beta

1.07

Frequently Asked Questions

What sell-side analysts currently cover shares of NuVasive?

The following sell-side analysts have issued research reports on NuVasive in the last twelve months: Barclays PLC, Morgan Stanley, StockNews.com, and Truist Financial Co..
View the latest analyst ratings for NUVA.

What is the current price target for NuVasive?

3 Wall Street analysts have set twelve-month price targets for NuVasive in the last year. Their average twelve-month price target is $51.33, suggesting a possible upside of 29.1%. Barclays PLC has the highest price target set, predicting NUVA will reach $58.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $45.00 for NuVasive in the next year.
View the latest price targets for NUVA.

What is the current consensus analyst rating for NuVasive?

NuVasive currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NUVA.

What other companies compete with NuVasive?

How do I contact NuVasive's investor relations team?

NuVasive's physical mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company's listed phone number is (858) 909-1800 and its investor relations email address is [email protected]. The official website for NuVasive is www.nuvasive.com. Learn More about contacing NuVasive investor relations.